Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Managing Editor, US Regulatory Analysis
Washington DC, USA
+26 year(s) experience
Pink Sheet
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
Topic Coronavirus
Pink Sheet
US FDA’s Medical Countermeasures Initiative authorities like emergency use authorization have not yet had much of an impact on drugs and biologics, but agency is committed to supporting a swift response to the new strain of coronavirus.
Pink Sheet
Differences in eligibility and evidentiary criteria between the US FDA's two expedited regulatory programs are reflected in a new guide; metrics to date suggest comparable success rates for designation requests under the two programs. Our infographics aid in understanding the programs.
Topic FDA
Pink Sheet
First four 351(k) BLA approvals highlight emerging FDA positions on issues from naming to the role of biosimilar-specific data.
Topic Biosimilars
Pink Sheet
05 Jul 2020
Pink Sheet
14 May 2020
Pink Sheet
12 May 2020
Pink Sheet
11 May 2020
Pink Sheet
05 May 2020
Pink Sheet
03 May 2020
Pink Sheet
28 Apr 2020
Pink Sheet
26 Apr 2020
Pink Sheet
19 Apr 2020
Pink Sheet
15 Apr 2020
Pink Sheet
13 Apr 2020
Pink Sheet
05 Apr 2020
Pink Sheet
03 Apr 2020
Pink Sheet
02 Apr 2020
Pink Sheet
30 Mar 2020
